Personalized Psychiatry Market Report 2026

The personalized psychiatry market size has grown rapidly in recent years. It will grow from $6.51 billion in 2025 to $7.46 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing awareness of mental health disorders, expansion of genetic testing in clinical psychiatry, rising adoption of telepsychiatry services, growing availability of mental health data platforms, increasing research funding for psychiatric precision medicine.

The personalized psychiatry market size is expected to see rapid growth in the next few years. It will grow to $12.73 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing demand for outcome-driven psychiatric treatments, rising integration of AI and genomics in mental healthcare, expansion of home-based and digital mental health solutions, growing emphasis on personalized drug efficacy, increasing investments in precision psychiatry platforms. Major trends in the forecast period include increasing adoption of pharmacogenomic-guided treatment planning, growing use of AI-driven clinical decision support tools, expansion of telepsychiatry-based personalized care models, rising integration of wearable and neuroimaging data, enhanced focus on early and accurate diagnosis.

The increasing prevalence of mental health issues is expected to drive the growth of the personalized psychiatry market in the coming years. Mental health issues encompass a broad range of conditions that affect an individual’s emotional, psychological, and social well-being. The rise in these conditions is largely linked to increasing stress and lifestyle-related challenges, including fast-paced work environments, poor work-life balance, and limited coping strategies. Personalized psychiatry addresses mental health issues by providing customized treatment plans based on individual biological, psychological, and lifestyle factors. This approach improves care effectiveness by reducing trial-and-error in treatment selection, resulting in faster recovery and better patient outcomes. For instance, in 2025, according to the National Alliance on Mental Illness and NextStep Solutions Behavioral Health, US-based health organizations reported that the prevalence of serious mental illness among adults was approximately 5.44% in 2023. Therefore, the growing burden of mental health issues is contributing to the growth of the personalized psychiatry market.

Major companies operating in the personalized psychiatry market are focusing on the development of advanced services, such as personalized telepsychiatry offerings, to expand access to individualized mental healthcare through flexible and patient-centric care models. Personalized telepsychiatry is a remote mental healthcare approach that delivers tailored psychiatric assessment and treatment based on an individual’s genetic, environmental, and lifestyle characteristics using digital communication platforms. For example, in April 2025, Alice’s Psychiatry & Wellness, a US-based psychiatry and wellness service provider, launched a clinic offering compassionate and personalized psychiatric care to adults across multiple states through both in-person and telepsychiatry services. This clinic incorporates pharmacogenetic testing to customize psychiatric medications according to each patient’s genetic profile, improving treatment effectiveness and minimizing adverse effects. It also utilizes virtual platforms and continuous care from dedicated providers to deliver accessible, consistent, and inclusive mental health support aligned with personalized psychiatry principles.

In March 2025, April Health Inc., a US-based behavioral health company, merged with Wysa Ltd. for an undisclosed amount. The merger is intended to combine Wysa’s AI-driven mental health support capabilities with April Health’s virtual behavioral health services, enhancing access to personalized mental healthcare through primary care channels. Wysa Ltd. is a US-based digital mental health company that uses artificial intelligence to deliver personalized and evidence-based psychiatric support.

Major companies operating in the personalized psychiatry market are Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company, Boehringer Ingelheim, Otsuka Pharmaceutical Co. Ltd., H. Lundbeck A/S, Neurocrine Biosciences, Spring Health, Neumora Therapeutics Inc., Atai Life Sciences, Valera Health, Compass Pathways, Genomind, Woebot Health, Meru Health, Alto Neuroscience, Arcara Personalized Psychiatry, Mind Sync Therapeutics, Starling Minds, HMNC Holding GmbH, Pear Therapeutics, Akili Interactive.

North America was the largest region in the personalized psychiatry market in 2025. The regions covered in the personalized psychiatry market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized psychiatry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the personalized psychiatry market by increasing costs of imported genetic testing kits, wearable monitoring devices, neuroimaging equipment, and advanced analytics software used across personalized treatment solutions. Healthcare providers and research institutions in North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces higher costs for software platforms and devices. These tariffs are increasing service delivery costs and slowing technology adoption in smaller clinics. However, they are also encouraging domestic development of diagnostic tools, localized software innovation, and regional manufacturing of wearable mental health technologies.

The personalized psychiatry market research report is one of a series of new reports that provides personalized psychiatry market statistics, including personalized psychiatry industry global market size, regional shares, competitors with a personalized psychiatry market share, detailed personalized psychiatry market segments, market trends and opportunities, and any further data you may need to thrive in the personalized psychiatry industry. This personalized psychiatry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personalized psychiatry is an individualized approach to mental healthcare that combines genetic, biological, environmental, and clinical information to tailor diagnosis, treatment planning, and therapeutic interventions for each patient, with the goal of improving clinical outcomes and reducing trial-and-error medication use. This approach is applied to enhance treatment effectiveness, limit adverse effects, and support early intervention by aligning psychiatric care with a patient’s specific biological and psychological characteristics.

The primary types of personalized psychiatry include products, services, and software. Personalized psychiatry products consist of customized medical tools, diagnostic solutions, or therapeutic options developed to support individualized mental health care based on a person’s genetic, biological, and behavioral profile. Technologies used in personalized psychiatry include genetic testing, artificial intelligence, neurostimulation technologies, and digital therapeutics. These technologies are applied in the treatment of conditions such as depression, anxiety disorders, bipolar disorder, schizophrenia, and attention-deficit hyperactivity disorder (ADHD), and are utilized by end users including clinics, hospitals, research institutes, and homecare settings.

The personalized psychiatry market consists of revenues earned by entities by providing services such as remote patient monitoring services for mental health, mental health coaching programs, medication management support, lifestyle and behavioral modification programs, cognitive assessment services, and in-home psychiatric care. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized psychiatry market also includes sales of biomarker-based diagnostic assays, neurofeedback equipment, point-of-care mental health diagnostic tools, personalized supplement formulations, and biosensor-integrated monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.